RESEARCH DIGEST · ABOUT THIS PUBLICATION
About TB-500 Telehealth: An Independent Research Publisher
A note on editorial scope, methodology, and the regulatory context of TB-500 as a research compound.
What This Site Is
TB-500 Telehealth is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain modifier — "telehealth" — reflects the search-intent landscape this site was built to address. It is not a claim about the site's services. There is no consultation funnel on this site, no booking widget, no prescriber referral, no treatment recommendation. The site is a literature digest. The word "telehealth" appears in the domain name because researchers and curious readers frequently pair it with compound names in their search queries; it does not appear in the site's editorial voice as a service offering.
Every quantitative claim on this site is attributed to a specific published study. The citation index on references provides the full bibliographic record. Readers who identify errors in citation or factual inaccuracies are encouraged to contact us.
TB-500 Regulatory Status
TB-500 (Ac-LKKTETQ) is not FDA approved for any human indication. It is a synthetic research compound — the seven-amino-acid active-site fragment of the endogenous protein thymosin beta-4 — and has not completed a published randomized controlled trial in humans as the specific heptapeptide. Phase I human safety data exist for the full-length thymosin beta-4 protein (a distinct 44-amino-acid molecule), administered intravenously in controlled clinical settings [11][12].
TB-500 is listed by WADA under Section S2 of the Prohibited List: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. It is prohibited at all times in sanctioned sport. Athletes competing under WADA-compliant anti-doping programs must not use TB-500 or thymosin beta-4. The detection window is approximately 30–45 days in urine and blood [1].
This site does not comment on the legality of TB-500 outside competitive sport, which varies by jurisdiction and is not a topic within our editorial scope.
Editorial Methodology
The research cited on this site was identified through PubMed, PubMed Central, and ClinicalTrials.gov search queries for "thymosin beta-4," "thymosin beta4," "TB-500," and "Ac-LKKTETQ." Studies were selected for inclusion based on relevance to the keyword inventory and the breadth of the research record — wound healing, cardiac repair, neuroprotection, hair follicle biology, pharmacokinetics, and anti-doping detection.
Quantitative claims are reported as stated in the original studies. Where a study uses the full-length thymosin beta-4 protein and the finding is extrapolated to TB-500, this limitation is noted. The "TB-500" designation in this site's title is the search-term frame; the research record reviewed is the thymosin beta-4 literature in full, with the heptapeptide fragment context noted throughout.
No claims on this site are invented. No citations are fabricated. If a claimed finding does not appear in the referenced study, we ask readers to bring this to our attention via the contact page.